EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment

Chenchen Ji, Feng Li, Yang Yuan, Huiqiang Zhang, Li Bian, Shaohua Zhang, Tao Wang, Jianbin Li, Zefei Jiang

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Chenchen Ji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Science and Technology Project, PLA general hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antibody-drug conjugates (ADCs) have been the preferred regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) after trastuzumab. Unfortunately, there is little data showing which ADCs should be chosen for those patients whose treatment with tyrosine kinase inhibitors (TKIs) failed. This study aims to analyze the efficacy and safety between novel anti-HER2 ADCs and trastuzumab emtansine (T-DM1) for those with TKIs failure. Materials and methods HER2-positive MBC using ADCs from January 2013 to June 2022 were included, and all of them were treated with TKIs. The primary study endpoint was progression-free survival (PFS), and the secondary study endpoints were objective response rate (ORR), clinical benefit rate (CBR), and safety.

Results

A total of 144 patients with 73 patients in the novel anti-HER2 ADCs group and 71 patients in the T-DM1 group. In these novel ADCs, 30 patients received trastuzumab deruxtecan (T-Dxd), 43 patients receive other novel ADCs. The median PFS in the novel ADCs group and T-DM1 group were 7.0 months versus 4.0 months, respectively, and ORR was 54.8% versus 22.5%, CBR was 65.8% versus 47.9%, respectively. In subgroups analysis, the PFS were both significantly improved in patients receiving T-Dxd and other novel ADCs compared with T-DM1. The most common grades 3-4 adverse events in the novel anti-HER-2 ADCs group were neutropenia (20.5%) and thrombocytopenia (28.1%) in the T-DM1 group.

Conclusions

In patients with HER2-positive MBC previously treated with TKIs, both T-Dxd and other novel anti-HER2 ADCs yielded statistically significant better PFS than T-DM1 did, with tolerable toxicities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsImmunoconjugatesFemaleHumansAdo-Trastuzumab EmtansineAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesTrastuzumabTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

antibody-drug conjugatesmetastatic breast cancertrastuzumab deruxtecantrastuzumab emtansinetyrosine kinase inhibitor

Substanzen

Ado-Trastuzumab EmtansineAntineoplastic AgentsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, People's Republic of China.
  • Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, People's Republic of China.

Förderung

  • Beijing Science and Technology Project
  • PLA general hospital

Zitieren

APA

Ji, C., Li, F., Yuan, Y., Zhang, H., Bian, L., Zhang, S., Wang, T., Li, J., & Jiang, Z. (2023). Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment. The Oncologist. https://doi.org/10.1093/oncolo/oyad127

Vancouver

Ji C, Li F, Yuan Y, Zhang H, Bian L, Zhang S, et al. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment. The Oncologist. 2023. doi:10.1093/oncolo/oyad127

BibTeX
@article{Ji2023,
  author = {Ji, Chenchen and Li, Feng and Yuan, Yang and Zhang, Huiqiang and Bian, Li and Zhang, Shaohua and Wang, Tao and Li, Jianbin and Jiang, Zefei},
  title = {Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad127}
}
Kostenlos starten →